WO1991011179A1 - Aerosol carriers - Google Patents

Aerosol carriers Download PDF

Info

Publication number
WO1991011179A1
WO1991011179A1 PCT/GB1991/000103 GB9100103W WO9111179A1 WO 1991011179 A1 WO1991011179 A1 WO 1991011179A1 GB 9100103 W GB9100103 W GB 9100103W WO 9111179 A1 WO9111179 A1 WO 9111179A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
carrier
dry powder
pharmacological agent
particulate
Prior art date
Application number
PCT/GB1991/000103
Other languages
French (fr)
Inventor
David Ganderton
Nuha Mohammed Kassem
Original Assignee
National Research Development Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Development Corporation filed Critical National Research Development Corporation
Priority to KR1019910701180A priority Critical patent/KR920700623A/en
Priority to CA002049302A priority patent/CA2049302C/en
Priority to AT91902428T priority patent/ATE98487T1/en
Priority to DE91902428T priority patent/DE69100792T2/en
Publication of WO1991011179A1 publication Critical patent/WO1991011179A1/en
Priority to NO91913731A priority patent/NO913731L/en
Priority to FI914460A priority patent/FI914460A0/en
Priority to US07/873,941 priority patent/US5376386A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Definitions

  • This invention relates to novel carrier materials useful in the formulation of pharmaceutical compositions especially dry powder compositions which are suitable for use in inhalation aerosols and to novel processes for the production of these materials.
  • nebulisers are relatively effective but they are expensive and bulky and as a result are mainly used in hospitals.
  • Pressurised metered dose inhalers require good co-ordination of actuation and inhalation which presents difficulties to many patients. They also require the use of propel lants which may be undesirable on environmental grounds.
  • the difficulties inherent in redisperslon of these agglomerates means that only a small proportion of the drug, may be as little as 5% is actually Injested via the lungs.
  • the present invention is directed to novel materials which are useful as carriers in dry powder inhaler compositions. We have discovered that the redispersion of drug particles from compositions comprising carriers is facilitated If the rugosity of the carrier particles is reduced.
  • the rugosity values of the materials are those measured by air permeametry.
  • our invention provides a particulate carrier sui tabl e for use in the preparation of pharmaceutical compositions having an average particle size of from 5.0 to 1000 microns and a rugosity of less than 1.75.
  • the measurement of rugosity by air permeametry produces a result which reflects the nature of the external surface of the material under test whereas measurements by techniques such as nitrogen adsorption reflect the total surface area including areas which are not accessible to particulate solids.
  • the rugosity of conventional excipients measured by air permeametry has been found to be at least 1.96 and generally greater than 2.0.
  • the carrier may be any crystalline non toxic material which is acceptable for use in pharmaceutical compositions which does not destabilise the pharmaceutically active materials with which it is formulated and which can be produced in a form having a rugosity of less than 1.75.
  • the preferred carriers are those which are known to be useful In dry powder inhaler compositions especially the mono-saccharldes such as lactose, mannitol, arablnose, xylitol and dextrose and their monohydrates, dissacharides such as maltose or sucrose and polysaccharldes such as starches, dextrins or dextrans.
  • mono-saccharldes such as lactose, mannitol, arablnose, xylitol and dextrose and their monohydrates
  • dissacharides such as maltose or sucrose
  • polysaccharldes such as starches, dextrins or dextrans.
  • the carrier comprises a particulate crystalline sugar such as glucose, fructose, mannitol, sucrose and most preferably lactose.
  • a particulate crystalline sugar such as glucose, fructose, mannitol, sucrose and most preferably lactose.
  • the average size of the particles of the carrier is preferably in the range 5 to 1000 ⁇ m and more preferably in the range 30 to 250 ⁇ m and most preferably 50 to 100 ⁇ m.
  • Typi cal ly at least 95% of the particles will be of a size which falls within this range, although the presence of significant quantities of fine material may be tolerable albeit less preferred.
  • the particulate sugar crystals which constitute a preferred aspect may be conveniently prepared by crystallisation from a solution which is preferably an aqueous solution.
  • the conditions under which crystallisation occurs should be controlled so as to favour the production of crystals having the desired low degree of rugosity. In general conditions which allow the crystals to form slowly are preferred whilst those which result in rapid crystallisation are correspondingly less preferred.
  • the utility of any particularly crystallisation process must be evaluated empirically and it is within the skill of the art to modify unsatisfactory procedures in order to produce the desired crystalline form of the novel excipients.
  • a sugar is precipitated from saturated aqueous solution by the addition of at least an equal volume of a water immiscible organic solvent and a quantity of a solvent which is miscible with both water and the aforesaid organic solvent which is at least 5% by volume of the total volume of the aqueous solution and the organic solvent constitute another aspect of this Invention.
  • the novel precipitation process may be conveniently carried out by mixing the solution and the solvents at ambient temperature and maintaining them at that temperature with thorough mixing until sugar crystals are formed.
  • Seeding of the saturated solution may be advantageous insofar as it may reduce the time required for crystal formation.
  • the size and morphology of the particulate material may be varied by controlling the conditions under which crystallisation and crystal growth occurs.
  • the choice of the organic water immiscible solvent and the miscible solvent may exert a considerable influence.
  • water immiscible solvents which may usefully be employed include hexane, chloroform cyclohexane, and toluene.
  • miscible solvents include acetone, alcohols and acetonltrile
  • the requirement that the miscible solvent is at least partially miscible with the water immiscible solvent (and with water) means that the choice of immiscible and miscible solvents are interdependent.
  • the preferred solvents are hexane (the immiscible solvent) and acetone (the miscible solvent).
  • the quantities of solvent employed are preferably such as to provide an excess volume of Immiscible solvent (typically at least 1.25 and more usually at least 1.5 times the volume of the saturated lactose solution being employed) and a relatively small quantity of the miscible solvent, say no more than 20% by volume being employed.
  • the solvent mixtures are preferably briskly agitated throughout the period of crystallisation and crystal growth.
  • the particles may be recovered by filtration and are usually washed, e.g. with the miscible solvent to remove excess mother liquor prior to drying.
  • the particles may be subject to further washes, e.g. with ethanol and ethanol/ water mixtures to improve the purity. These washes also serve to reduce the quantities of very fine particles present in the product which may be preferable.
  • the form and size of the crystals may be determined by optical and/or scanning electron miscroscopy.
  • the rugosity of the particles may be determined by air permeametry which relates the volumetric flow rate (Q) of air through a packed bed of powder compressed to a known porosity to the internal surface area So of the powder.
  • the rugosity can then be expressed as the ratio So/Sd where Sd is the theoretical surface area (assuming the particles to be spherical).
  • Sd is the theoretical surface area (assuming the particles to be spherical).
  • the smoothness of the particles may be readily apparent under the scanning electron microscope and this may render the determination of their rugosity superfluous.
  • the particles will have a rugosity of no more than 1.5 and most preferably no more than 1.3.
  • novel carrier materials are preferably used directly as the sole excipient in dry powder inhalents. However, they may be used in admixture with other excipients although, in general, it is preferred that the excipient comprises at least 80% and preferably at least 95% by weight of the novel carrier materials of this invention.
  • novel excipients may be admixed with any suitable pharmacological agent or agents in order to provide a dry powder inhalent composition.
  • suitable pharmacological agent or agents in order to provide a dry powder inhalent composition.
  • the average size of the particles of the pharmacologi cal active agent or agents will be such as to facilitate their passage deep into the lower part of the respiratory tract.
  • the average particle size should be within the range 0.1 to 10 microns, more preferably 0.5 to 5.0 microns and at least 95% of the particles should have a size within these preferred ranges.
  • the amount of pharmacological agent incorporated into the inhalent composition will generally be from 0.1 to 50% by weight of the composition. The amount will vary with the desired dosage of any particular agent.
  • the novel compositions have the advantage that a higher proportion of the pharmacological agent is available to the lower part of the respiratory tract and hence the proportion of any particular agent may be reduced, to one half or even one quarter by weight of the composition compared to a conventional formulation. This increased availability of the active agent also enables agents to be administered by oral inhalation which would not previously have been administered by this route. Thus, agents other than those conventionally employed to treat ailments of the respiratory tract may be administered by this means.
  • Examples of pharmacological agents which have been administered by oral inhalation include agents with an anti-histamine and anti-allergic action such as sodium cromoglycate and ketotifen, ⁇ -agonists, anti-cholinergies such as ipratropium bromide, oxytropium bromide and thiazinamide chloride, sympathomimetic amines such as terbutaline, salbutamol, clenbuterol, pirbuterol, reproterol, procaterol and fenoterol, steroids especially cortlcosteroids such as beclamethasone dipropionate, flurisolide budesonide and mucolyties such as ambroxol.
  • agents with an anti-histamine and anti-allergic action such as sodium cromoglycate and ketotifen, ⁇ -agonists, anti-cholinergies such as ipratropium bromide, oxytropium bromide and thiazinamide chloride, sympathomimetic amine
  • pharmacological agents which might usefully be incorporated into the novel compositions of this invention include hypnotics, sedatives,, tranquillisers, anti-inflammatory agents, anti-hlstamines, anti-tussives, anti-convulsants, musclerelaxants, anti-spasmodics, cardiovascular agents, anti-bacterials such as pentamidine, anti-biotics and hypoglycaemic agents.
  • compositions of this invention may contain a bronchodilator as an additional active agent.
  • a bronchodilator as an additional active agent.
  • the amount of any such bronchodilator will normally not exceed the dosage conventionally employed in its application by inhalation and will preferably be less than is conventionally employed.
  • useful bronchodilators include isoprenaline, rimiterol, ephedrine, ibuterol, isoetharine, fenoterol, carbuterol, clinbuterol, hexaprenaline, salmifamol, soterenol, trlmetoquinol, orciprena ⁇ ne, terbutaline and salbutamol or a pharmaceutically acceptable salt thereof.
  • the invention finds particular application in the administration of agents which cannot be conveniently administered by other routes.
  • peptldes such as insulin and growth hormones, ACTH and LHRH analogues.
  • compositions of this invention may contain other ingredients such as colouring matter of flavouring agents such as those which are conventionally incorporated into dry powder inhalant compositions.
  • flavouring agents such as those which are conventionally incorporated into dry powder inhalant compositions.
  • Such ingredients are present in only minor quantities, e.g. less than 10% and more preferably less than 5% by weight of the composition.
  • Such materials will also preferably comprise particles of size comparable with that of the carrier, e.g. 30 to 150 microns.
  • compositions may be formulated by dry mixing the active agent and the excipient.
  • the composition may conveniently be encapsulated, e.g. in a hard gelatin capsule suitable for use in the inhalers which are readily available.
  • the compositions may be formulated into capsules containing a single dose of active material which can be inserted into an appropriate inhaler. Alternatively, they may be placed in a larger container and placed in an inhaler which is designed so as to meter a single dose of the composition into Its air passage upon activation.
  • the compositions may be dispensed using any of the conventional inhalers. Their use in dry powder inhalers of all types is strongly preferred. Such inhalers which contain a composition according to this invention are novel and form a further aspect of the invention.
  • Salbutamol sulphate BP was micronised using an air jet mill (Fryma jet mill JM 80) at a pressure of 7.5 bar and a feed rate of 5g/min.
  • the particle size distribution was determined microscopically by measuring the diameter of 500 particles.
  • Lactose (lactochem Pharmaceuticals), in a size range of 63-90 ⁇ m was obtained by sieving (Alpine air jet sieve).
  • Recrystallised lactose was obtained by crystallisation of the original lactose in a partially miscible mixture of water, hexane and acetone.
  • Lactose was dissolved In water (2 to 1) in a beaker at 80C. The solution was cooled to room temperature, 75 ml of hexane (Reagent grade) was added to 50ml of the saturated solution and agitated at 500 rpm with a paddle type agitator with four blades, acetone (10ml) (Reagent grade) was then added. The mixture was stirred for 8-12 h, during which time lactose crystals formed. These were washed with acetone, absolute ethanol, 60% ethanol in water and absolute ethanol respectively and dried.
  • hexane Reagent grade
  • the particle size of the recrystallised lactose was determined with the optical microscope and was found to be in the range of 60-90 ⁇ m.
  • the examination of the carrier surface was by scanning electron microscopy.
  • the rugosity of the lactose before and after crystallisation was determined by compressing a mass of powder equal to its density to a known porosity in the cell of a Fisher Sub-Sieve Sizer.
  • the flow rate through the bed at a fixed pressure differential is transcribed by the instrument to an average particle diameter dm.
  • Samples of drug-lactose blends were prepared in a ratio of 1:67.5 by mixing the micronised drug and the treated lactose with a spatula. The homogeneity of the mixtures was verified by the assay of ten 30 mg samples. The coefficient of variation of the sample content ranged between 1.1-3.0 for the mixtures studied. 27.4 mg + 1.4 mg of the mixtures containing 400 ⁇ g of salbutamol sulphate was filled into hard gelatin capsules (size 3).
  • FIG. 1 A diagram of the apparatus is shown in Fig. 1.
  • a powder inhaler device (1) Rotahaler, Allen & Hanbury's Ltd.
  • contai ni ng an encapsulated dose was assembled in a line conducting dried filtered air at up to 200 1/min.
  • the powder was blown into a vertical diffuser (2) 550 mm in length with 2 mm and 70 mm inlet and outlet diameters respectively.
  • Sharp edged conical probes (3) with diameters calculated to give isokinetic sampling were placed at midstream of the diffuser.
  • Air was drawn at 28.3 1/min through a sampler (4) (Anderson 1 CFM Ambient) which comprises a preseparator stage that collects particles with an aerodynamic diameter larger than 10 ⁇ m, and seven separation stages. Stages 0 to 2 have approximate cut-off diameters of 5.5-10 ⁇ m and stages 3 to 7 collect particles less than 5.5 ⁇ m.
  • the mass median diameter of salbutamol sulphate was 2.8 ⁇ m with a geometric standard deviation of 1.3.
  • a double blind randomised cross-over trial was carried out to compare the effects of a commercial formulation comprising salbutamol sulphate and a conventional lactose carrier with a composition according to this invention containing the same proportions of salbutamol sulphate and a modified lactose of this Invention prepared in the manner described in Example 1.
  • FEV Fluorescence Equivalent
  • the trial was carried out using conventional dry powder Inhalers.
  • the commercial formulation produced a mean increase in FEV, of 21.4%.
  • the formulation according to this invention produced a mean increase in FEV, of 27.5%.
  • the difference 6.1% was significant (paired t-test; p ⁇ 0.05; confidence interval 0.64-11.52).

Abstract

Pharmaceutical excipients useful in dry powder inhalents comprise particles having a rugosity (measured by air permeametry) of less than 1.75. The use of these carriers increases the amount of drug injested by the patient using a dry powder inhaler. The preferred excipients are crystalline sugars such as lactose which may conveniently be prepared by controlled crystallisation from an aqueous medium.

Description

AEROSOL CARRIERS
This invention relates to novel carrier materials useful in the formulation of pharmaceutical compositions especially dry powder compositions which are suitable for use in inhalation aerosols and to novel processes for the production of these materials.
The administration of pharmacological agents by inhalation has been recognised as a valuable technique, particularly in the treatment of diseases of the respiratory tract. The efficacy of the technique has been limited by difficulty in making appropriate dosages available to the lungs. The delivery systems currently available are nebulisers, pressurised metered dose inhalers and dry powder inhalers. Nebulisers are relatively effective but they are expensive and bulky and as a result are mainly used in hospitals. Pressurised metered dose inhalers require good co-ordination of actuation and inhalation which presents difficulties to many patients. They also require the use of propel lants which may be undesirable on environmental grounds.
A variety of dry powder inhalers have been developed. All of them rely upon the inspiratory effort of the patient to produce finely divided drug particles which are available to the lungs. Also there have been various proposals for dry powder formulations suitable for use in these Inhalers in order to improve the efficacy of the treatment. For example International Patent Application WO 87/05213 describes a carrier which comprises microgranules of a conglomerate of one or more solid water soluble diluents with a lubricant such as magnesium stearate. In practice another difficulty is caused by the tendency of the drug particles which are necessarily of a relatively small size to agglomerate either with themselves or more usually with particles of the carrier materials with which they are admixed. The difficulties inherent in redisperslon of these agglomerates means that only a small proportion of the drug, may be as little as 5% is actually Injested via the lungs. The present invention is directed to novel materials which are useful as carriers in dry powder inhaler compositions. We have discovered that the redispersion of drug particles from compositions comprising carriers is facilitated If the rugosity of the carrier particles is reduced. The rugosity values of the materials are those measured by air permeametry.Accordingly, from one aspect our invention provides a particulate carrier sui tabl e for use in the preparation of pharmaceutical compositions having an average particle size of from 5.0 to 1000 microns and a rugosity of less than 1.75. The measurement of rugosity by air permeametry produces a result which reflects the nature of the external surface of the material under test whereas measurements by techniques such as nitrogen adsorption reflect the total surface area including areas which are not accessible to particulate solids. The rugosity of conventional excipients measured by air permeametry has been found to be at least 1.96 and generally greater than 2.0. The carrier may be any crystalline non toxic material which is acceptable for use in pharmaceutical compositions which does not destabilise the pharmaceutically active materials with which it is formulated and which can be produced in a form having a rugosity of less than 1.75. The preferred carriers are those which are known to be useful In dry powder inhaler compositions especially the mono-saccharldes such as lactose, mannitol, arablnose, xylitol and dextrose and their monohydrates, dissacharides such as maltose or sucrose and polysaccharldes such as starches, dextrins or dextrans.
Preferably the carrier comprises a particulate crystalline sugar such as glucose, fructose, mannitol, sucrose and most preferably lactose.
The average size of the particles of the carrier is preferably in the range 5 to 1000 μm and more preferably in the range 30 to 250 μm and most preferably 50 to 100 μm. Typi cal ly at least 95% of the particles will be of a size Which falls within this range, although the presence of significant quantities of fine material may be tolerable albeit less preferred.
The particulate sugar crystals which constitute a preferred aspect, may be conveniently prepared by crystallisation from a solution which is preferably an aqueous solution. The conditions under which crystallisation occurs should be controlled so as to favour the production of crystals having the desired low degree of rugosity. In general conditions which allow the crystals to form slowly are preferred whilst those which result in rapid crystallisation are correspondingly less preferred. The utility of any particularly crystallisation process must be evaluated empirically and it is within the skill of the art to modify unsatisfactory procedures in order to produce the desired crystalline form of the novel excipients.
Processes in which a sugar is precipitated from saturated aqueous solution by the addition of at least an equal volume of a water immiscible organic solvent and a quantity of a solvent which is miscible with both water and the aforesaid organic solvent which is at least 5% by volume of the total volume of the aqueous solution and the organic solvent constitute another aspect of this Invention. The novel precipitation process may be conveniently carried out by mixing the solution and the solvents at ambient temperature and maintaining them at that temperature with thorough mixing until sugar crystals are formed.
Seeding of the saturated solution may be advantageous insofar as it may reduce the time required for crystal formation.
The size and morphology of the particulate material may be varied by controlling the conditions under which crystallisation and crystal growth occurs. In particular, the choice of the organic water immiscible solvent and the miscible solvent may exert a considerable influence. Examples of water immiscible solvents which may usefully be employed include hexane, chloroform cyclohexane, and toluene. Examples of miscible solvents include acetone, alcohols and acetonltrile The requirement that the miscible solvent is at least partially miscible with the water immiscible solvent (and with water) means that the choice of immiscible and miscible solvents are interdependent. In the case of crystallisation of solutions of lactose, the preferred solvents are hexane (the immiscible solvent) and acetone (the miscible solvent). The quantities of solvent employed are preferably such as to provide an excess volume of Immiscible solvent (typically at least 1.25 and more usually at least 1.5 times the volume of the saturated lactose solution being employed) and a relatively small quantity of the miscible solvent, say no more than 20% by volume being employed.
The solvent mixtures are preferably briskly agitated throughout the period of crystallisation and crystal growth. After the crystal growth phase the particles may be recovered by filtration and are usually washed, e.g. with the miscible solvent to remove excess mother liquor prior to drying. The particles may be subject to further washes, e.g. with ethanol and ethanol/ water mixtures to improve the purity. These washes also serve to reduce the quantities of very fine particles present in the product which may be preferable.
The form and size of the crystals may be determined by optical and/or scanning electron miscroscopy. The rugosity of the particles may be determined by air permeametry which relates the volumetric flow rate (Q) of air through a packed bed of powder compressed to a known porosity to the internal surface area So of the powder. The rugosity can then be expressed as the ratio So/Sd where Sd is the theoretical surface area (assuming the particles to be spherical). In practice the smoothness of the particles may be readily apparent under the scanning electron microscope and this may render the determination of their rugosity superfluous. Preferably the particles will have a rugosity of no more than 1.5 and most preferably no more than 1.3.
The novel carrier materials are preferably used directly as the sole excipient in dry powder inhalents. However, they may be used in admixture with other excipients although, in general, it is preferred that the excipient comprises at least 80% and preferably at least 95% by weight of the novel carrier materials of this invention.
The novel excipients may be admixed with any suitable pharmacological agent or agents in order to provide a dry powder inhalent composition. Such compositions are believed to be novel and constitute a further aspect of the invention.
The average size of the particles of the pharmacologi cal active agent or agents will be such as to facilitate their passage deep into the lower part of the respiratory tract. In general the average particle size should be within the range 0.1 to 10 microns, more preferably 0.5 to 5.0 microns and at least 95% of the particles should have a size within these preferred ranges.
The amount of pharmacological agent incorporated into the inhalent composition will generally be from 0.1 to 50% by weight of the composition. The amount will vary with the desired dosage of any particular agent. However, the novel compositions have the advantage that a higher proportion of the pharmacological agent is available to the lower part of the respiratory tract and hence the proportion of any particular agent may be reduced, to one half or even one quarter by weight of the composition compared to a conventional formulation. This increased availability of the active agent also enables agents to be administered by oral inhalation which would not previously have been administered by this route. Thus, agents other than those conventionally employed to treat ailments of the respiratory tract may be administered by this means.
Examples of pharmacological agents which have been administered by oral inhalation include agents with an anti-histamine and anti-allergic action such as sodium cromoglycate and ketotifen, β-agonists, anti-cholinergies such as ipratropium bromide, oxytropium bromide and thiazinamide chloride, sympathomimetic amines such as terbutaline, salbutamol, clenbuterol, pirbuterol, reproterol, procaterol and fenoterol, steroids especially cortlcosteroids such as beclamethasone dipropionate, flurisolide budesonide and mucolyties such as ambroxol.
Examples of other pharmacological agents which might usefully be incorporated into the novel compositions of this invention include hypnotics, sedatives,, tranquillisers, anti-inflammatory agents, anti-hlstamines, anti-tussives, anti-convulsants, musclerelaxants, anti-spasmodics, cardiovascular agents, anti-bacterials such as pentamidine, anti-biotics and hypoglycaemic agents.
Where appropriate the compositions of this invention may contain a bronchodilator as an additional active agent. The amount of any such bronchodilator will normally not exceed the dosage conventionally employed in its application by inhalation and will preferably be less than is conventionally employed. Examples of useful bronchodilators Include isoprenaline, rimiterol, ephedrine, ibuterol, isoetharine, fenoterol, carbuterol, clinbuterol, hexaprenaline, salmifamol, soterenol, trlmetoquinol, orciprenaϋne, terbutaline and salbutamol or a pharmaceutically acceptable salt thereof.
The invention finds particular application in the administration of agents which cannot be conveniently administered by other routes. A particular example are peptldes such as insulin and growth hormones, ACTH and LHRH analogues.
In addition to the novel carrier and the pharmacologically active agent or agents the compositions of this invention may contain other ingredients such as colouring matter of flavouring agents such as those which are conventionally incorporated into dry powder inhalant compositions. Preferably such ingredients are present in only minor quantities, e.g. less than 10% and more preferably less than 5% by weight of the composition. Such materials will also preferably comprise particles of size comparable with that of the carrier, e.g. 30 to 150 microns.
The compositions may be formulated by dry mixing the active agent and the excipient. The composition may conveniently be encapsulated, e.g. in a hard gelatin capsule suitable for use in the inhalers which are readily available. The compositions may be formulated into capsules containing a single dose of active material which can be inserted into an appropriate inhaler. Alternatively, they may be placed in a larger container and placed in an inhaler which is designed so as to meter a single dose of the composition into Its air passage upon activation. The compositions may be dispensed using any of the conventional inhalers. Their use in dry powder inhalers of all types is strongly preferred. Such inhalers which contain a composition according to this invention are novel and form a further aspect of the invention.
The invention is illustrated by the following examples.
Example 1
Salbutamol sulphate BP was micronised using an air jet mill (Fryma jet mill JM 80) at a pressure of 7.5 bar and a feed rate of 5g/min. The particle size distribution was determined microscopically by measuring the diameter of 500 particles.
Lactose (lactochem Pharmaceuticals), in a size range of 63-90 μm was obtained by sieving (Alpine air jet sieve).
Recrystallised lactose was obtained by crystallisation of the original lactose in a partially miscible mixture of water, hexane and acetone.
Lactose was dissolved In water (2 to 1) in a beaker at 80C. The solution was cooled to room temperature, 75 ml of hexane (Reagent grade) was added to 50ml of the saturated solution and agitated at 500 rpm with a paddle type agitator with four blades, acetone (10ml) (Reagent grade) was then added. The mixture was stirred for 8-12 h, during which time lactose crystals formed. These were washed with acetone, absolute ethanol, 60% ethanol in water and absolute ethanol respectively and dried.
The particle size of the recrystallised lactose was determined with the optical microscope and was found to be in the range of 60-90 μm. The examination of the carrier surface was by scanning electron microscopy. The rugosity of the lactose before and after crystallisation was determined by compressing a mass of powder equal to its density to a known porosity in the cell of a Fisher Sub-Sieve Sizer. The flow rate through the bed at a fixed pressure differential is transcribed by the instrument to an average particle diameter dm. The specific surface So was calculated from the equation So = 6 x 104
dm p where p is the powder density. The rugosity before crystallisation was found to be 2.36 whilst the rugosity after recrystallisatlon was found to be 1.16.
Samples of drug-lactose blends were prepared in a ratio of 1:67.5 by mixing the micronised drug and the treated lactose with a spatula. The homogeneity of the mixtures was verified by the assay of ten 30 mg samples. The coefficient of variation of the sample content ranged between 1.1-3.0 for the mixtures studied. 27.4 mg + 1.4 mg of the mixtures containing 400 μg of salbutamol sulphate was filled into hard gelatin capsules (size 3).
Simulation of patient use
A diagram of the apparatus is shown in Fig. 1. A powder inhaler device (1) (Rotahaler, Allen & Hanbury's Ltd.) contai ni ng an encapsulated dose was assembled in a line conducting dried filtered air at up to 200 1/min. On actuation, the powder was blown into a vertical diffuser (2) 550 mm in length with 2 mm and 70 mm inlet and outlet diameters respectively. Sharp edged conical probes (3) with diameters calculated to give isokinetic sampling were placed at midstream of the diffuser. Air was drawn at 28.3 1/min through a sampler (4) (Anderson 1 CFM Ambient) which comprises a preseparator stage that collects particles with an aerodynamic diameter larger than 10 μm, and seven separation stages. Stages 0 to 2 have approximate cut-off diameters of 5.5-10 μm and stages 3 to 7 collect particles less than 5.5 μm. A final filter trapped particles less than 0.4 μm.
Experiments were conducted at air flow rates of 60 and 150 1/min, each using 10 capsules. After deposition, the inhalation device with the capsules, the preseparator, stages 0 to 2, stages 3 to 7 and the filter of the impactor were separately rinsed with methanol and the washings assayed by HPLC using reversed phase column packed with octadecylsilane (30 cm 3.9 mm i.d.) using 35% 0.013 M ammonium acetate in methanol as the mobile phase and a variable wavelength detector set at 276 nm. The total amount of salbutamol sulphate recovered from each stage was calculated and expressed as a percentage of the total dose discharged.
The mass median diameter of salbutamol sulphate was 2.8 μm with a geometric standard deviation of 1.3.
The results of the effect of surface properties of a carrier on drug deposition are shown in Table I.
Table I
Percentage of drug deposited at various stages using regular lactose and recrystallised lactose.
At air flow rate of 601 /min.
Figure imgf000011_0001
Example 2
A double blind randomised cross-over trial was carried out to compare the effects of a commercial formulation comprising salbutamol sulphate and a conventional lactose carrier with a composition according to this invention containing the same proportions of salbutamol sulphate and a modified lactose of this Invention prepared in the manner described in Example 1. Eleven moderate to severe stable atopic asthmatic patients took part in the trial (FEV, <80% predicted; >15% reversibility. FEV is Forced Expiratory Volume in 1 second). The trial was carried out using conventional dry powder Inhalers. The commercial formulation produced a mean increase in FEV, of 21.4%. The formulation according to this invention produced a mean increase in FEV, of 27.5%. The difference 6.1% was significant (paired t-test; p <0.05; confidence interval 0.64-11.52).

Claims

What we claim is
1. A particulate carrier suitable for use in dry powder inhaler compositions having an average particle size of from 5.0 to 1000 microns and a rugosity of less than 1.75.
2. A carri er accordi ng to Cl aim 1 characterised in that the carrier is a particulate crystalline sugar.
3. A carrier according to Claim 2 characterised in that the crystalline sugar is selected from the group comprising glucose, fructose, mannitol, sucrose and lactose.
4. A carrier according to Claim 3 characterised in that the crystalline sugar is lactose.
5. A carrier according to any of Claim 1 to 4 characterised in that the particles have an average particle size of from 30 to
250 microns.
6. A carrier according to any of the preceding claims characterised in that the particles have a rugosity of not more than 1.5.
7. A dry powder inhalent composition which comprises a excipient in admixture with at least one pharmacological agent which is characterised in that the excipient comprises a particulate carrier according to any of Claims 1 to 6.
8. A composition according to Claim 7 characterised in that the excipient comprises at least 80% by weight of a particulate carrier according to any of Claims 1 to 6.
9. A composition according to Claim 8 characterised in that the excipient consists essentially of a particulate carrier according to any of Claims 1 to 6.
10. A composition according to any of Claims 7 to 9 characterised in that it comprises from 0.1 to 50% by weight of a pharmacological agent.
11. A composition according to any of Claims 6 to 10 characterised in that the pharmacological agent is a particulate solid having an average particle size of from 0.1 to 10.0 microns.
12. A composition according to any of Claims 6 to 11 characterised in that the pharmacological agent is a β agonist, a steroid or sodium chromoglycoate.
13. A composition according to any of Claims 6 to 11 characterised in that the pharmacological agent is a peptide.
14. A composition according to Claim 13 characterised in that the pharmacological agent is selected from the group comprising insulin and growth hormones such as ACTH and LNRH analogues.
15. A composition according to any of claims 6 to 11 characterised in that the pharmacological agent is an anti-bacterial agent.
16. A composition according to claim 15 characterised in that the anti-bacterial agent is pentamidine.
17. A process for the production of a particulate carrier according to any of Claims 1 to 6 which comprises precipitating the carrier from a saturated aqueous solution by the addition of at least an equal volume of a water immiscible organic solvent and a quantity of a solvent which is miscible with water and with the water immiscible solvent which is at least 5% by volume of the volume of the aqueous solution.
18. A process according to Claim 16 characterised in that the water Immiscible solvent is selected from the group comprising hexane, chloroform cyclohexane and toluene.
19. A process according to either of Claims 17 or 18 characterised in that the water miscible solvent is selected from the group comprising acetone, ethanol propanol or butanol and acetonitrile.
20. An encapsulated dry powder inhalent composition according to any of claims 7 to 14.
21. A dry powder inhaler characterised in that it contains a dry powder inhalent composition according to any of claims 7 to 14 or 20.
22. A carrier according to Claim 1 substantially as herei nbefore described with reference to the foregoing examples.
PCT/GB1991/000103 1990-01-24 1991-01-24 Aerosol carriers WO1991011179A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1019910701180A KR920700623A (en) 1990-01-24 1991-01-24 Aerosol carrier
CA002049302A CA2049302C (en) 1990-01-24 1991-01-24 Aerosol carriers
AT91902428T ATE98487T1 (en) 1990-01-24 1991-01-24 AEROSOL CARRIER.
DE91902428T DE69100792T2 (en) 1990-01-24 1991-01-24 AEROSOL CARRIERS.
NO91913731A NO913731L (en) 1990-01-24 1991-09-23 Aerosol carriers.
FI914460A FI914460A0 (en) 1990-01-24 1991-09-23 AEROSOLBAERARE.
US07/873,941 US5376386A (en) 1990-01-24 1992-04-27 Aerosol carriers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909001635A GB9001635D0 (en) 1990-01-24 1990-01-24 Aerosol carriers
GB9001635.3 1990-01-24

Publications (1)

Publication Number Publication Date
WO1991011179A1 true WO1991011179A1 (en) 1991-08-08

Family

ID=10669832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/000103 WO1991011179A1 (en) 1990-01-24 1991-01-24 Aerosol carriers

Country Status (15)

Country Link
US (1) US5254330A (en)
EP (1) EP0464171B1 (en)
JP (1) JP3100626B2 (en)
KR (1) KR920700623A (en)
AT (1) ATE98487T1 (en)
AU (1) AU635616B2 (en)
CA (1) CA2049302C (en)
DE (1) DE69100792T2 (en)
FI (1) FI914460A0 (en)
GB (2) GB9001635D0 (en)
HU (1) HUT59821A (en)
IE (1) IE910222A1 (en)
NO (1) NO913731L (en)
PT (1) PT96567A (en)
WO (1) WO1991011179A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017663A1 (en) * 1992-03-10 1993-09-16 Fisons Plc Pharmaceutical inhalation compositions
WO1993025198A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Ultrafine powder for inhalation and production thereof
DE4425255A1 (en) * 1994-07-16 1996-01-18 Asta Medica Ag Formulation for inhalation application
WO1997021838A1 (en) * 1995-12-11 1997-06-19 Eridania Beghin-Say Microcrystalline sugars or sugar-alcohols; method for preparing the same
US5817028A (en) * 1994-02-25 1998-10-06 Central Sydney Area Health Service Method and device for the provocation of air passage narrowing and/or the induction of sputum
EP0876814A1 (en) * 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
WO1999027911A1 (en) * 1997-12-03 1999-06-10 Fujisawa Pharmaceutical Co., Ltd. Soft-pellet drug and process for the preparation thereof
WO2000035417A1 (en) * 1998-12-11 2000-06-22 Pharmachemie B.V. Pharmaceutical preparation for inhalation of an opioid
US6387394B1 (en) 1995-04-07 2002-05-14 Penwest Pharmaceuticals Co. Controlled release insufflation carrier for medicaments
WO2002045682A1 (en) * 2000-12-08 2002-06-13 School Of Pharmacy, University Of London Particulate inhalation carrier
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007855A1 (en) * 1987-04-09 1988-10-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
DE69535897D1 (en) 1994-03-07 2009-01-22 Nektar Therapeutics Method and composition for the pulmonary delivery of insulin
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5641510A (en) * 1994-07-01 1997-06-24 Genentech, Inc. Method for treating capsules used for drug storage
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
EP0806945B1 (en) * 1994-12-22 2003-04-23 AstraZeneca AB Therapeutic preparation for inhalation containing parathyro d hormone, pth
MX9704550A (en) 1994-12-22 1997-10-31 Astra Ab Aerosol drug formulations.
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
SE9501384D0 (en) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
AU1860697A (en) * 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
US5699789A (en) * 1996-03-11 1997-12-23 Hendricks; Mark R. Dry powder inhaler
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
JP2001507701A (en) 1996-12-31 2001-06-12 インヘイル・セラピューティック・システムズ・インコーポレーテッド Method for spray drying a solution of a hydrophobic drug having a hydrophilic excipient and a composition made by the method
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
SE9701956D0 (en) 1997-05-23 1997-05-23 Astra Ab New composition of matter
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
GB9806477D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved crystals
US6489183B1 (en) * 1998-07-17 2002-12-03 Micron Technology, Inc. Method of manufacturing a taped semiconductor device
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
CZ303154B6 (en) 1998-11-13 2012-05-09 Jagotec Ag Dry powder formulation for inhalation containing magnesium stearate
ATE289825T1 (en) 1999-04-21 2005-03-15 1355540 Ontario Inc METHACOLINE OR HISTAMINE FORMULATIONS FOR DETECTING ASTHMA
EP2280020B1 (en) 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ITMI991582A1 (en) * 1999-07-16 2001-01-16 Chiesi Farma Spa DUST CONSTITUTED FROM PARTICLES HAVING THE PERFECTLY SMOOTH SURFACE FOR USE AS VEHICLES FOR THE PREPARATION OF INALA MIXTURES
US6759386B2 (en) * 2000-04-06 2004-07-06 Wayne P. Franco Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
AU2001279771A1 (en) * 2000-07-20 2002-02-05 Campina B.V. Carrier material for dry powder inhalation
MXPA03002991A (en) * 2000-10-09 2004-05-05 3M Innovative Properties Co Medicinal aerosol formulations.
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
DE10141376A1 (en) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Process for the preparation of inhalable powders
DE10141377A1 (en) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Scattering process for the production of powder formulations
US20050013862A1 (en) * 2001-09-05 2005-01-20 Vectura Limited Functional powders for oral delivery
BR0214279A (en) * 2001-11-19 2005-12-20 Becton Dickinson Co Pharmaceutical compositions in particulate form
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
AU2003209475A1 (en) * 2002-03-07 2003-09-16 Vectura Limited Fast melt multiparticulate formulations for oral delivery
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
WO2003086358A1 (en) * 2002-04-12 2003-10-23 Campina Nederland Holding B.V. Excipient for use in dry powder inhalation preparations
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EP1501479A1 (en) * 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
WO2003094965A2 (en) * 2002-05-08 2003-11-20 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
GB0210527D0 (en) * 2002-05-08 2002-06-19 Univ Bath Process for the treatment of particles for use in pharmaceutical formulations
WO2005004845A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
EP1663188B1 (en) * 2003-09-12 2016-08-10 Newron Sweden AB Treatment of disorders of the nervous system
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
CA2576410A1 (en) * 2003-09-18 2006-03-31 Norton Healthcare Ltd. Particles
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
MXPA06012240A (en) 2004-04-23 2007-01-31 Cydex Inc Dpi formulation containing sulfoalkyl ether cyclodextrin.
DK1786784T3 (en) 2004-08-20 2011-02-14 Mannkind Corp Catalysis of diketopiperazine synthesis
PL2322180T3 (en) 2004-08-23 2015-10-30 Mannkind Corp Diketopiperazine salts for drug delivery
EP1858528A2 (en) * 2005-02-10 2007-11-28 Glaxo Group Limited Process for crystallizing lactose particles for use in pharmaceutical formulations
CN101155590A (en) 2005-02-10 2008-04-02 葛兰素集团有限公司 Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
EP1917301B1 (en) * 2005-08-05 2014-04-23 3M Innovative Properties Company Compositions exhibiting improved flowability
CN104324366B (en) 2005-09-14 2016-10-05 曼金德公司 Method for preparation of drug based on improving the active agent affinity to crystalline microparticle surfaces
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
MX360812B (en) 2006-02-22 2018-11-16 Mannkind Corp A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent.
AU2007238114B2 (en) 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
US20090291146A1 (en) * 2006-08-09 2009-11-26 Glaxo Group Limited Process for manufacturing lactose
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
DE202009018480U1 (en) 2008-06-13 2012-01-26 Mannkind Corp. Dry powder inhaler and drug delivery system
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MX2010014240A (en) 2008-06-20 2011-03-25 Mankind Corp An interactive apparatus and method for real-time profiling of inhalation efforts.
TWI532497B (en) 2008-08-11 2016-05-11 曼凱公司 Use of ultrarapid acting insulin
EP2191821A1 (en) 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR101875969B1 (en) 2009-06-12 2018-07-06 맨카인드 코포레이션 Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
TR201007250A2 (en) 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Formulation containing cellobiose.
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
BR122020008875B8 (en) 2011-04-01 2022-12-06 Mannkind Corp BLISTER PACKAGING AND METHOD OF MANUFACTURING A BLISTER PACKAGE
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
JP2014520848A (en) * 2011-07-08 2014-08-25 ファイザー・リミテッド Process for the preparation of type 1 fluticasone propionate
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
KR102264177B1 (en) 2012-07-12 2021-06-11 맨카인드 코포레이션 Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
BR112015023168B1 (en) 2013-03-15 2021-08-10 Mannkind Corporation COMPOSITION OF 3,6-BIS(N-FUMARYL-4-AMINOBUTYL)-2,5-CRYSTALLINE DICETOPIPERAZINE, METHOD OF PRODUCTION OF 3,6-BIS(N-FUMARYL-4-AMINOBUTYL)-2,5-DICETOPIPERAZINE PARTICLES AND USE OF A CRYSTALLINE DICETOPIPERAZINE COMPOSITION
CN114848614A (en) 2013-07-18 2022-08-05 曼金德公司 Heat stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE292149C (en) *
DE2851489A1 (en) * 1977-11-30 1979-05-31 Fisons Ltd PHARMACEUTICAL PREPARATION
WO1987005213A1 (en) * 1986-03-04 1987-09-11 Chiesi Farmaceutici S.P.A. New pharmaceutical compositions for inhalation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7812207L (en) * 1977-12-01 1979-06-02 Welsh Nat School Med APPARATUS, PROCEDURE AND MANUFACTURED PRODUCTS FOR USE IN THE ADMINISTRATION OF ANTIHISTAMINES
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
GB2077100B (en) * 1980-04-30 1985-04-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
EP0248051A1 (en) * 1985-11-29 1987-12-09 FISONS plc Pharmaceutical composition including sodium cromoglycate
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE292149C (en) *
DE2851489A1 (en) * 1977-11-30 1979-05-31 Fisons Ltd PHARMACEUTICAL PREPARATION
WO1987005213A1 (en) * 1986-03-04 1987-09-11 Chiesi Farmaceutici S.P.A. New pharmaceutical compositions for inhalation

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607662A (en) * 1992-03-10 1997-03-04 Fisons, Plc Pharmaceutical inhalation compositions
WO1993017663A1 (en) * 1992-03-10 1993-09-16 Fisons Plc Pharmaceutical inhalation compositions
US5972388A (en) * 1992-06-12 1999-10-26 Teijin Limited Ultrafine particle power for inhalation and method for production thereof
WO1993025198A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Ultrafine powder for inhalation and production thereof
US5817028A (en) * 1994-02-25 1998-10-06 Central Sydney Area Health Service Method and device for the provocation of air passage narrowing and/or the induction of sputum
DE4425255A1 (en) * 1994-07-16 1996-01-18 Asta Medica Ag Formulation for inhalation application
WO1996002231A1 (en) * 1994-07-16 1996-02-01 Asta Medica Aktiengesellschaft Inhalation composition
US6284287B1 (en) 1994-07-16 2001-09-04 Asta Medica Ag Particulate formulation for administration by inhalation
US7172766B2 (en) 1995-04-07 2007-02-06 Penwest Pharmaceuticals Company Controlled release insufflation carrier for medicaments
US6387394B1 (en) 1995-04-07 2002-05-14 Penwest Pharmaceuticals Co. Controlled release insufflation carrier for medicaments
WO1997021838A1 (en) * 1995-12-11 1997-06-19 Eridania Beghin-Say Microcrystalline sugars or sugar-alcohols; method for preparing the same
AU707137B2 (en) * 1995-12-11 1999-07-01 Eridania Beghin-Say Microcrystalline sugars or sugar-alcohols; a process for the preparation thereof
US6015466A (en) * 1995-12-11 2000-01-18 Eridania Beghin-Say Microcrystalline sugars or sugar-alcohols; method for preparing the same
WO1998050015A1 (en) * 1997-05-07 1998-11-12 Pharlyse, Societe Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
US7090870B1 (en) 1997-05-07 2006-08-15 Francis Vanderbist Dry power inhaler excipient, process for its preparation and pharmaceutical compositions containing it
EP0876814A1 (en) * 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
WO1999027911A1 (en) * 1997-12-03 1999-06-10 Fujisawa Pharmaceutical Co., Ltd. Soft-pellet drug and process for the preparation thereof
WO2000035417A1 (en) * 1998-12-11 2000-06-22 Pharmachemie B.V. Pharmaceutical preparation for inhalation of an opioid
WO2002045682A1 (en) * 2000-12-08 2002-06-13 School Of Pharmacy, University Of London Particulate inhalation carrier
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US10172853B2 (en) 2007-02-11 2019-01-08 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile

Also Published As

Publication number Publication date
PT96567A (en) 1991-10-15
CA2049302C (en) 2001-05-29
CA2049302A1 (en) 1991-07-25
NO913731D0 (en) 1991-09-23
GB9001635D0 (en) 1990-03-21
AU635616B2 (en) 1993-03-25
GB2240337A (en) 1991-07-31
DE69100792D1 (en) 1994-01-27
EP0464171B1 (en) 1993-12-15
NO913731L (en) 1991-11-21
DE69100792T2 (en) 1994-04-14
HU913284D0 (en) 1992-01-28
GB2240337B (en) 1993-02-24
IE910222A1 (en) 1991-07-31
KR920700623A (en) 1992-08-10
EP0464171A1 (en) 1992-01-08
FI914460A0 (en) 1991-09-23
GB9101551D0 (en) 1991-03-06
AU7155991A (en) 1991-08-21
JPH04504427A (en) 1992-08-06
JP3100626B2 (en) 2000-10-16
US5254330A (en) 1993-10-19
ATE98487T1 (en) 1994-01-15
HUT59821A (en) 1992-07-28

Similar Documents

Publication Publication Date Title
US5254330A (en) Aerosol carriers
US5376386A (en) Aerosol carriers
US6153224A (en) Carrier particles for use in dry powder inhalers
US6989155B1 (en) Powders
US7022311B1 (en) Powdery inhalational preparations and process for producing the same
JP5021149B2 (en) Medical aerosol formulation
US20100092453A1 (en) Method of producing porous microparticles
WO2002017882A1 (en) Solid peptide preparations for inhalation, and the production thereof
US20080292713A1 (en) Respirable Powders
Westmeier et al. Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment
Kulkarni et al. Effect of Formulation Excipients on Aerosolisation Performance of Budesonide
Shah et al. OPTIMIZATION OF INHALATION PERFORMANCE AND DRUG RELEASE OF COMBINATION DRY POWDER FOR INHALATION BASED ON SELECTION OF EXCIPIENTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2049302

Country of ref document: CA

Ref document number: 914460

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1991902428

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991902428

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1991902428

Country of ref document: EP